Heterozygote APOE4 carriers have a four times higher risk of developing AD, rising to a fifteen times higher risk in those who possess two copies of the APOE4 gene3,4 and recent work suggests that by 80 years almost all APOE4 homozygotes will have developed AD pathology and symptoms5. The gene discussed is APOE; the disease is Alzheimer disease.